Patents by Inventor Sylvain Baize

Sylvain Baize has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity
    Patent number: 11638751
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 2, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM
    Publication number: 20210205436
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Application
    Filed: November 30, 2020
    Publication date: July 8, 2021
    Inventors: Sylvain BAIZE, Audrey PAGE, Xavier CARNEC, Mathieu Jean Simon MATEO, Stephanie REYNARD, Alexandra FIZET
  • Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
    Patent number: 10849969
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 1, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • LASSA VACCINE
    Publication number: 20200308555
    Abstract: The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
    Type: Application
    Filed: December 20, 2018
    Publication date: October 1, 2020
    Inventors: Mathieu MATEO, Sylvain BAIZE, Frédéric TANGY
  • RECOMBINANT MOPEIA VIRUS AND VACCINE PLATFORM
    Publication number: 20180303927
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Application
    Filed: October 24, 2016
    Publication date: October 25, 2018
    Inventors: Sylvain BAIZE, Audrey PAGE, Xavier CARNEC, Mathieu Jean Simon MATEO, Stephanie REYNARD, Alexandra FIZET
  • Methods and pharmaceutical compositions for the treatment of ebola virus disease
    Patent number: 10098879
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: October 16, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BORDEAUX, CHU DE BORDEAUX, TOYAMA CHEMICAL CO., LTD
    Inventors: Denis Malvy, Sylvain Baize, Xavier De Lamballerie, Hervé Raoul, Cédric Laouenan, Jeremie Guedj, France Mentre